Bluebird Bio Company Profile (NASDAQ:BLUE)

About Bluebird Bio

Bluebird Bio logobluebird bio, Inc. is a biotechnology company. The Company is focused on developing transformative gene therapies for severe genetic and rare diseases and in the field of T cell-based immunotherapy. Its gene therapy clinical programs include LentiGlobin product candidate to treat transfusion-dependent B-thalassemia (TDT) and severe sickle cell disease (SCD), and Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD), a rare hereditary neurological disorder. Its oncology programs are built using lentiviral gene delivery and T cell engineering, with a focus on developing T cell-based immunotherapies, including chimeric antigen receptor (CAR) and T cell receptor (TCR) T cell therapies. Its oncology program, bb2121, is a CAR T cell product candidate targeting B-cell maturation antigen, or BCMA, in multiple myeloma. It also offers discovery research programs utilizing megaTALs/homing endonuclease gene editing technologies for use across its pipeline.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: BLUE
  • CUSIP:
Key Metrics:
  • Previous Close: $49.97
  • 50 Day Moving Average: $52.63
  • 200 Day Moving Average: $47.03
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -8.20
  • P/E Growth: -0.04
  • Market Cap: $1.90B
  • Outstanding Shares: 37,169,000
  • Beta: 1.86
Additional Links:
Companies Related to Bluebird Bio:

Analyst Ratings

Consensus Ratings for Bluebird Bio (NASDAQ:BLUE) (?)
Ratings Breakdown: 4 Hold Ratings, 13 Buy Ratings
Consensus Rating:Buy (Score: 2.76)
Consensus Price Target: $85.21 (66.34% upside)

Analysts' Ratings History for Bluebird Bio (NASDAQ:BLUE)
DateFirmActionRatingPrice TargetDetails
8/18/2016Goldman Sachs Group Inc.Reiterated RatingBuy$135.00View Rating Details
8/18/2016Piper Jaffray Cos.Reiterated RatingOverweight$117.00 -> $95.00View Rating Details
8/4/2016Leerink SwannReiterated RatingOutperform$67.00View Rating Details
8/4/2016Maxim GroupReiterated RatingBuy$105.00 -> $85.00View Rating Details
8/3/2016WedbushReiterated RatingOutperform$117.00View Rating Details
7/14/2016Jefferies GroupReiterated RatingPositive$80.00View Rating Details
6/29/2016BTIG ResearchReiterated RatingBuy$72.00View Rating Details
6/2/2016Cantor FitzgeraldInitiated CoverageHold$42.00View Rating Details
5/10/2016Janney Montgomery ScottReiterated RatingBuy$91.00View Rating Details
5/5/2016Wells Fargo & Co.Reiterated RatingBuyView Rating Details
2/23/2016Roth CapitalReiterated RatingNeutral$62.00View Rating Details
12/7/2015JPMorgan Chase & Co.DowngradeBuyView Rating Details
12/7/2015Bank of America Corp.DowngradeBuy -> Neutral$149.00 -> $102.00View Rating Details
12/7/2015Morgan StanleyDowngradeOverweight -> Equal Weight$143.00 -> $69.00View Rating Details
11/16/2015Cowen and CompanyReiterated RatingOutperformView Rating Details
11/5/2015Oppenheimer Holdings Inc.Reiterated RatingOutperform$162.00View Rating Details
9/18/2015BMO Capital MarketsInitiated CoverageBuy$14.00View Rating Details
6/15/2015SunTrust Banks Inc.Reiterated RatingBuy$205.00 -> $230.00View Rating Details
(Data available from 8/27/2014 forward)


Earnings History for Bluebird Bio (NASDAQ:BLUE)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/3/2016Q2($1.44)($1.59)$2.01 million$1.55 millionViewN/AView Earnings Details
5/4/2016Q1($1.23)($1.52)$4.50 million$1.50 millionViewN/AView Earnings Details
2/24/2016Q4($1.11)($1.29)$3.21 million$1.47 millionViewN/AView Earnings Details
8/6/2015Q215($0.78)($1.57)$8.60 million$4.94 millionViewN/AView Earnings Details
5/6/2015Q115($0.61)($0.76)$6.20 million$6.30 millionViewN/AView Earnings Details
2/25/2015Q414($0.57)($0.67)$6.20 million$6.30 millionViewN/AView Earnings Details
11/12/2014Q314($0.50)($0.61)$6.20 million$6.40 millionViewN/AView Earnings Details
8/12/2014Q214($0.45)($0.06)$6.15 million$6.30 millionViewN/AView Earnings Details
5/13/2014Q114($0.32)($0.44)$6.23 million$6.30 millionViewN/AView Earnings Details
3/5/2014($0.31)($0.34)ViewN/AView Earnings Details
11/12/2013Q3($0.25)($0.26)$5.59 million$6.39 millionViewN/AView Earnings Details
8/8/2013Q213($0.35)($2.13)$4.85 million$6.30 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Bluebird Bio (NASDAQ:BLUE)
Current Year EPS Consensus Estimate: $-6.09 EPS
Next Year EPS Consensus Estimate: $-6.25 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 201610($1.38)($0.92)($1.21)
Q2 201610($1.56)($0.99)($1.36)
Q3 20169($1.62)($1.28)($1.48)
Q4 20169($1.67)($1.34)($1.54)
Q1 20172($1.68)($1.62)($1.65)
Q2 20172($1.75)($1.62)($1.69)
Q3 20172($1.83)($1.63)($1.73)
Q4 20171($1.38)($1.38)($1.38)
(Data provided by Zacks Investment Research)


Dividend History for Bluebird Bio (NASDAQ:BLUE)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for Bluebird Bio (NASDAQ:BLUE)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/3/2016Eric SullivanInsiderSell416$59.00$24,544.00View SEC Filing  
7/27/2016Eric SullivanInsiderSell2,912$55.01$160,189.12View SEC Filing  
7/20/2016Eric SullivanInsiderSell2,807$45.04$126,427.28View SEC Filing  
7/15/2016David DavidsonInsiderSell1,000$45.08$45,080.00View SEC Filing  
6/16/2016Philip D GregoryInsiderSell2,931$39.52$115,833.12View SEC Filing  
6/15/2016David DavidsonInsiderSell1,000$40.11$40,110.00View SEC Filing  
5/16/2016David DavidsonInsiderSell1,000$38.73$38,730.00View SEC Filing  
4/15/2016David DavidsonInsiderSell1,000$49.63$49,630.00View SEC Filing  
3/15/2016David DavidsonInsiderSell1,000$46.13$46,130.00View SEC Filing  
2/16/2016David DavidsoninsiderSell1,000$45.18$45,180.00View SEC Filing  
1/15/2016David DavidsoninsiderSell1,000$44.39$44,390.00View SEC Filing  
12/15/2015David DavidsoninsiderSell1,000$58.55$58,550.00View SEC Filing  
12/8/2015Nick LeschlyCEOBuy9,682$51.75$501,043.50View SEC Filing  
11/16/2015David DavidsoninsiderSell2,000$70.99$141,980.00View SEC Filing  
11/10/2015Jeffrey T. WalshCOOSell11,000$74.60$820,600.00View SEC Filing  
10/15/2015David DavidsoninsiderSell2,000$79.70$159,400.00View SEC Filing  
10/12/2015Jeffrey T. WalshCOOSell11,000$88.06$968,660.00View SEC Filing  
10/9/2015Jason ColeSVPSell5,000$86.91$434,550.00View SEC Filing  
10/5/2015Daniel LynchDirectorSell3,000$100.41$301,230.00View SEC Filing  
9/17/2015Daniel LynchDirectorSell1,500$140.06$210,090.00View SEC Filing  
9/15/2015David DavidsoninsiderSell2,000$129.98$259,960.00View SEC Filing  
9/10/2015Jeffrey T. WalshCOOSell11,000$130.02$1,430,220.00View SEC Filing  
9/9/2015Jason ColeSVPSell2,000$136.56$273,120.00View SEC Filing  
9/8/2015Daniel LynchDirectorSell7,000$132.75$929,250.00View SEC Filing  
9/8/2015Nick LeschlyCEOSell125,000$135.24$16,905,000.00View SEC Filing  
9/1/2015James MandellDirectorSell1,500$125.96$188,940.00View SEC Filing  
7/20/2015Eric SullivanInsiderSell1,126$163.36$183,943.36View SEC Filing  
7/15/2015David DavidsonInsiderSell2,000$165.96$331,920.00View SEC Filing  
7/10/2015Jeffrey T WalshCOOSell11,000$158.63$1,744,930.00View SEC Filing  
7/9/2015Jason ColeSVPSell5,000$158.19$790,950.00View SEC Filing  
6/15/2015David DavidsonInsiderSell2,000$183.34$366,680.00View SEC Filing  
6/10/2015Jeffrey T WalshCOOSell11,000$179.70$1,976,700.00View SEC Filing  
6/1/2015Mitchell H FinerInsiderSell15,000$190.25$2,853,750.00View SEC Filing  
4/20/2015Mitchell H FinerInsiderSell15,000$126.03$1,890,450.00View SEC Filing  
4/15/2015David DavidsonInsiderSell2,000$130.18$260,360.00View SEC Filing  
4/10/2015Jeffrey T WalshCOOSell21,000$126.21$2,650,410.00View SEC Filing  
4/2/2015Eric SullivanInsiderSell2,998$117.81$353,194.38View SEC Filing  
3/10/2015Jeffrey T WalshCOOSell10,500$110.06$1,155,630.00View SEC Filing  
3/2/2015David DavidsonInsiderSell4,000$94.84$379,360.00View SEC Filing  
1/12/2015Jeffrey T WalshCOOSell10,500$103.57$1,087,485.00View SEC Filing  
1/2/2015David DavidsonInsiderSell4,000$90.01$360,040.00View SEC Filing  
12/19/2014John MaraganoreDirectorBuy2,352$85.00$199,920.00View SEC Filing  
12/10/2014Jeffrey T WalshCOOSell43,500$78.06$3,395,610.00View SEC Filing  
12/8/2014David DavidsonInsiderSell15,000$46.10$691,500.00View SEC Filing  
12/3/2014David DavidsonInsiderSell3,000$41.65$124,950.00View SEC Filing  
12/1/2014Mitchell H FinerInsiderSell18,000$39.70$714,600.00View SEC Filing  
12/1/2014Nick LeschlyCEOSell2,417$39.70$95,954.90View SEC Filing  
11/3/2014David DavidsonInsiderSell3,000$41.68$125,040.00View SEC Filing  
11/3/2014Nick LeschlyCEOSell25,000$41.68$1,042,000.00View SEC Filing  
10/24/2014Nick LeschlyCEOSell33,900$40.22$1,363,458.00View SEC Filing  
10/10/2014Jeffrey T WalshCOOSell7,500$33.16$248,700.00View SEC Filing  
10/9/2014Steven GillisDirectorSell115,000$35.25$4,053,750.00View SEC Filing  
10/8/2014Mitchell H FinerInsiderSell34,518$33.52$1,157,043.36View SEC Filing  
10/7/2014Steven GillisDirectorSell57,435$35.43$2,034,922.05View SEC Filing  
10/2/2014Steven GillisDirectorSell91,165$35.28$3,216,301.20View SEC Filing  
10/1/2014David DavidsonInsiderSell3,000$34.55$103,650.00View SEC Filing  
10/1/2014Nick LeschlyCEOSell8,000$34.55$276,400.00View SEC Filing  
9/12/2014Robert I TepperDirectorSell125,000$36.54$4,567,500.00View SEC Filing  
9/10/2014Jeffrey T WalshCOOSell7,500$37.02$277,650.00View SEC Filing  
9/2/2014David DavidsonInsiderSell3,000$38.00$114,000.00View SEC Filing  
9/2/2014Nick LeschlyCEOSell10,300$38.45$396,035.00View SEC Filing  
8/11/2014Jeffrey T WalshCOOSell7,500$34.26$256,950.00View SEC Filing  
8/1/2014David DavidsonInsiderSell3,000$33.62$100,860.00View SEC Filing  
8/1/2014Nick LeschlyCEOSell8,000$33.62$268,960.00View SEC Filing  
7/14/2014John MaraganoreDirectorBuy2,941$34.00$99,994.00View SEC Filing  
7/10/2014Jeffrey T WalshCOOSell7,500$33.20$249,000.00View SEC Filing  
7/3/2014Nick LeschlyCEOSell22,283$39.86$888,200.38View SEC Filing  
7/1/2014David DavidsonInsiderSell3,000$39.55$118,650.00View SEC Filing  
6/20/2014Nick LeschlyCEOSell17,075$40.06$684,024.50View SEC Filing  
6/16/2014Jeffrey T WalshCOOSell1,500$39.86$59,790.00View SEC Filing  
6/16/2014Mitchell H FinerInsiderSell10,000$39.84$398,400.00View SEC Filing  
6/16/2014Nick LeschlyCEOSell42,925$40.02$1,717,858.50View SEC Filing  
6/10/2014Jeffrey T WalshCOOSell6,000$24.23$145,380.00View SEC Filing  
6/2/2014Mitchell H FinerInsiderSell8,000$22.21$177,680.00View SEC Filing  
6/2/2014Nick LeschlyCEOSell5,000$22.21$111,050.00View SEC Filing  
5/14/2014Jeffrey WalshCOOSell1,500$20.03$30,045.00View SEC Filing  
5/12/2014Jeffrey WalshCOOSell4,500$18.93$85,185.00View SEC Filing  
5/1/2014David DavidsonInsiderSell4,000$19.85$79,400.00View SEC Filing  
5/1/2014Nick LeschlyCEOSell5,000$20.07$100,350.00View SEC Filing  
4/10/2014Jeffrey WalshCOOSell6,000$21.29$127,740.00View SEC Filing  
1/22/2014Linda BainVPSell2,500$25.11$62,775.00View SEC Filing  
1/17/2014Robert TepperDirectorSell307,000$22.43$6,886,010.00View SEC Filing  
1/16/2014Mitchell FinerInsiderSell10,000$23.52$235,200.00View SEC Filing  
1/14/2014Robert TepperDirectorSell340,000$21.90$7,446,000.00View SEC Filing  
1/10/2014Jeffrey WalshCOOSell6,000$21.98$131,880.00View SEC Filing  
1/3/2014David DavidsonInsiderSell15,000$20.88$313,200.00View SEC Filing  
1/3/2014Linda BainVPSell5,000$20.89$104,450.00View SEC Filing  
(Data available from 1/1/2013 forward)


Latest Headlines for Bluebird Bio (NASDAQ:BLUE)
News IconIntraday Active Biotech Stocks News: bluebird bio (NASDAQ:BLUE), TetraLogic Pharmaceuticals (NASDAQ:TLOG) - The Voice Registrar (NASDAQ:BLUE) - August 25 at 9:18 PM
News IconEye Catching Stocks: bluebird bio Inc (NASDAQ:BLUE), Advanced Micro Devices, Inc. (NASDAQ:AMD) - NYSE Journal (press release) (NASDAQ:BLUE) - August 25 at 9:18 PM logoNotable Two Hundred Day Moving Average Cross - BLUE (NASDAQ:BLUE) - August 25 at 8:43 AM logoETF’s with exposure to bluebird bio, Inc. : August 23, 2016 (NASDAQ:BLUE) - August 23 at 3:53 PM logoWill bluebird bio, Inc. (NASDAQ:BLUE) Hit $117 Price Target? - Investor Newswire (NASDAQ:BLUE) - August 21 at 3:45 PM
News IconBluebird Bio Inc. (NASDAQ: BLUE) Overweight Rating Reiterated at ... - BNB Daily (blog) (NASDAQ:BLUE) - August 20 at 8:52 AM logoClear Skies For Bluebird Bio To Enter A New Inflection Point (NASDAQ:BLUE) - August 18 at 12:16 PM logoPiper Jaffray Provides 2H16 Outlook for bluebird bio Inc (BLUE); Cuts Price Target (NASDAQ:BLUE) - August 17 at 9:19 PM logoETF’s with exposure to bluebird bio, Inc. : August 12, 2016 (NASDAQ:BLUE) - August 12 at 3:22 PM logoBLUEBIRD BIO, INC. Financials (NASDAQ:BLUE) - August 11 at 3:59 PM logobluebird bio, Inc. :BLUE-US: Earnings Analysis: Q2, 2016 By the Numbers : August 11, 2016 (NASDAQ:BLUE) - August 11 at 12:02 PM logoHow These Biotech Stocks are Faring? -- bluebird bio, Sage ... - PR Newswire (press release) (NASDAQ:BLUE) - August 10 at 3:20 PM logobluebird bio Inc. Earnings: Waiting for Data - Motley Fool (NASDAQ:BLUE) - August 10 at 6:57 AM logoBRIEF-Proteostasis Therapeutics says appointment of James M. Detore as CFO (NASDAQ:BLUE) - August 8 at 9:19 PM
News Icon2 Biotech Stocks News And Price Trends: bluebird bio, Inc. (NASDAQ:BLUE), Achillion Pharmaceuticals, Inc. (NASDAQ ... - The Voice Registrar (NASDAQ:BLUE) - August 8 at 3:56 PM logoBlue Solutions :BLUE-FR: Earnings Analysis: For the six months ended December 31, 2015 : August 8, 2016 (NASDAQ:BLUE) - August 8 at 8:41 AM logobluebird bio Inc. (BLUE) Jumps 7.42% on August 05 - (NASDAQ:BLUE) - August 6 at 11:35 AM
News IconThursday’s business agenda (NASDAQ:BLUE) - August 5 at 9:14 PM logoWhy bluebird bio, Inc. Stock Gained 25.3% in July (NASDAQ:BLUE) - August 5 at 9:14 PM
News IconTrading the Biotech News: Keryx Biopharmaceuticals Inc. (NASDAQ:KERX), bluebird bio, Inc. (NASDAQ:BLUE) - The Voice Registrar (NASDAQ:BLUE) - August 5 at 3:52 PM logoWhy bluebird bio, Inc. Stock Gained 25.3% in July - Motley Fool (NASDAQ:BLUE) - August 5 at 12:17 PM logo[$$] Bluebird Bio's Target Price Cut to $85 (NASDAQ:BLUE) - August 5 at 12:17 PM logobluebird bio Inc. Tumbles 9.4% After Reporting a Wider-Than-Expected Q2 Loss - Motley Fool (NASDAQ:BLUE) - August 4 at 9:38 PM
News Iconbluebird bio Reports Second Quarter 2016 Financial Results and Recent Operational Progress (NASDAQ:BLUE) - August 4 at 3:59 PM logoLeerink Swann Analyst Reiterates Outperform Rating on bluebird bio Inc (BLUE) (NASDAQ:BLUE) - August 4 at 3:59 PM logoBluebird Bio Inc.: bluebird bio Reports Second Quarter 2016 Financial Results and Recent Operational Progress (NASDAQ:BLUE) - August 4 at 3:59 PM
News IconAttentive Stocks in Active Notes- bluebird bio (NASDAQ:BLUE), Entravision Communications (NYSE:EVC), Treehouse ... - Seneca Globe (NASDAQ:BLUE) - August 4 at 12:29 PM
News IconActive biotech company shares in the news: bluebird bio, Inc. (NASDAQ:BLUE), Galena Biopharma, Inc. (NASDAQ ... - The Voice Registrar (NASDAQ:BLUE) - August 4 at 12:29 PM logobluebird bio to Present at Wedbush PacGrow Healthcare Conference (NASDAQ:BLUE) - August 4 at 12:29 PM logobluebird bio Inc. (BLUE) Jumps 7.22% on August 03 - (NASDAQ:BLUE) - August 3 at 9:33 PM logoBluebird reports 2Q loss (NASDAQ:BLUE) - August 3 at 9:33 PM
News IconUpcoming Earnings Report: bluebird bio, Inc. (NASDAQ:BLUE) - The Voice Registrar (NASDAQ:BLUE) - July 31 at 8:02 AM
News Icon3 Biotech Stocks to Buy on Sale (NASDAQ:BLUE) - July 30 at 2:54 PM logoWill bluebird bio, Inc. (NASDAQ:BLUE) Surprise Analysts? - Investor Newswire (NASDAQ:BLUE) - July 28 at 10:32 PM logoLonza : Amendment to Combined Synopsis/Solicitation - RFQ Lonza Walkersville, Inc. 4D-Nucleofector- (NASDAQ:BLUE) - July 28 at 4:55 PM
News IconBluebird bio Inc. (NASDAQ:BLUE) announced the presentation of pre-clinical data from its megaTAL genome editing ... - Inside Trade (NASDAQ:BLUE) - July 28 at 12:39 PM logobluebird bio Inc. (BLUE) Jumps 11.24% on July 27 - (NASDAQ:BLUE) - July 28 at 12:39 PM logo5 Reasons bluebird bio Inc. Took Flight Today - Motley Fool (NASDAQ:BLUE) - July 28 at 12:39 PM logoBLUE Crosses Above Key Moving Average Level (NASDAQ:BLUE) - July 27 at 9:39 PM
News IconUltragenyx Pharmaceutical Inc (NASDAQ:RARE): That’s How Members Are Up 7% In Short Term, Bought At $57.40 (NASDAQ:BLUE) - July 27 at 3:55 PM logobluebird bio (BLUE) Shares are Up 7.61% - Trade Calls (NASDAQ:BLUE) - July 25 at 9:58 PM logoIs $117 Price Target Attainable For bluebird bio, Inc. (NASDAQ:BLUE)? - Investor Newswire (NASDAQ:BLUE) - July 24 at 8:36 AM
News IconEquity Roundup: Stock Performance Focus on bluebird bio, Inc. (NASDAQ:BLUE) - Press Telegraph (NASDAQ:BLUE) - July 23 at 8:08 AM logoStocks inside Analysts Spotlight: Cigna Corporation (NYSE:CI) , bluebird bio, Inc. (NASDAQ:BLUE) - Street Updates (NASDAQ:BLUE) - July 22 at 12:02 PM
News Iconbluebird bio, Inc. (NASDAQ:BLUE): Sell-Side Ratings and Company Earnings Glance - Engelwood Daily (NASDAQ:BLUE) - July 21 at 3:54 PM
News IconRecent Insider Trading Alert: bluebird bio Inc (NASDAQ:BLUE ... - Post Registrar (NASDAQ:BLUE) - July 21 at 3:54 PM logobluebird bio Inc. (BLUE) Jumps 6.91% on July 20 - (NASDAQ:BLUE) - July 21 at 3:54 PM
News IconAnalyst Recommendations Watch: bluebird bio, Inc. (NASDAQ:BLUE) - News Oracle (NASDAQ:BLUE) - July 21 at 3:54 PM
News Iconbluebird bio Inc Increases Again; Strong Momentum for Buyers - Consumer Eagle (NASDAQ:BLUE) - July 21 at 3:54 PM
News IconOne Kendall Sq. sold (NASDAQ:BLUE) - July 20 at 11:55 AM


Bluebird Bio (NASDAQ:BLUE) Chart for Saturday, August, 27, 2016

Last Updated on 8/27/2016 by Staff